Author:
Abstract
Keywords
Abstract
Cell and gene therapy is a method used to treat genetically based diseases that currently have no effective treatments. The number of products available for cell and gene therapy has been rising annually in recent years. By 2025, the FDA predicts that it will have approved 10 to 20 novel cell and gene therapy products annually. The FDA's current list of authorized gene treatments includes 26 gene and cell-based products. The FDA and EMA have approved 8 cell-based and gene therapy products in 2022. We summarized the gene therapy medications authorized in 2022 in this review. Two gene therapy drugs (Skysona and Zynteglo) that were approved this year were previously approved and stopped marketing in Europe since the European market price could not be agreed upon. This year, the FDA approved the use of these two medications.